MyoGene Bio

MyoGene Bio

This company develops gene-editing therapies to treat patients with Duchenne muscular dystrophy by restoring production of the dystrophin protein.

Exonics

This company develops gene editing therapies for patients with Duchenne muscular dystrophy and other severe genetic neuromuscular diseases.

MyoPax

This company develops muscle regeneration cell and gene therapies for patients with congenital malformations, trauma, hereditary dystrophies and muscle wasting disorders.

Exonics Therapeutics

The company develops gene editing therapies for patients with Duchenne muscular dystrophy and other genetic neuromuscular diseases.

Myosana Therapeutics, Inc.

This company develops non-viral gene therapies for patients with cardiac and neuromuscular diseases, including Duchenne muscular dystrophy and X-linked myotubular myopathy.

Bamboo Therapeutics

This company develops gene therapies for patients with rare neuromuscular and central nervous system diseases, including Duchenne muscular dystrophy.

Capricor

This biotechnology company develops cell and exosome-based therapies to treat Duchenne muscular dystrophy and other serious diseases for patients.

Satellos Bioscience

This company develops oral small molecule drugs to restore muscle regeneration for patients with Duchenne muscular dystrophy and other degenerative muscle diseases.